Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells

Chemico-Biological Interactions

Volumn 176, Issue 1, 2008, Pages 9-18

  Gavelová, Martina ^a   Hladíková, Jana ^a   Vildová, Lenka ^a   Novotná, Romana ^a   Vondráček, Jan ^b   Krčmář, Pavel ^b   Machala, Miroslav ^b   Skálová, Lenka ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b VETERINARY RESEARCH INSTITUTE   (Czech Republic)

Author keywords

AKR1C3; Breast cancer; Carbonyl reduction; CBR1; Doxorubicin; Oracin

Indexed keywords

CARBONYL REDUCTASE; CARBONYL REDUCTASE 1; DOXORUBICIN; ORACIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MICROSOME; PROTEIN EXPRESSION;

3-HYDROXYSTEROID DEHYDROGENASES; ALCOHOL OXIDOREDUCTASES; BIOTRANSFORMATION; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME INDUCTION; ENZYME INHIBITORS; ETHANOLAMINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; ISOQUINOLINES; KINETICS; METHACRYLATES; OXIDATION-REDUCTION; PHENYLPROPIONATES; QUERCETIN; RNA, MESSENGER; SUBCELLULAR FRACTIONS;

EID: 52949150776     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2008.07.011     Document Type: Article

References (38)

1. Soldan M., Ax W., Plebuch M., Koch L., and Maser E. Cytostatic drug resistence. Role of phase I daunorubicin metabolism in cancer cells. In: Weiner H., et al. (Ed). Enzymology and Molecular Biology of Carbonyl Metabolism vol. 7 (1999), Kluwer Academic/Plenum Publishers, New York 529-538
2. Soldan M., Netter K.J., and Maser E. Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem. Pharmacol. 51 (1996) 117-123
3. Forrest G.L., and Gonzalez B. Carbonyl reductase. Chem. Biol. Interact. 129 (2000) 21-40
4. Hyndman D., Bauman D.R., Heredia V.V., and Penning T.M. The aldo-keto reductase superfamily homepage. Chem. Biol. Interact. 143-144 (2003) 621-631
5. Rosemond M.J., and Walsh J.S. Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab. Rev. 36 (2004) 335-361
6. Matsunaga T., Shintani S., and Hara A. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab. Pharmacokinet. 21 (2006) 1-18
7. Hoffmann F., and Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab. Rev. 39 (2007) 87-144
8. Oppermann U. Carbonyl reductases: the complex relationships of mammalian carbonyl- and quinone-reducing. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 293-322
9. Jin Y., and Penning T.M. Aldo-keto reductases and bioactivation/detoxication. Annu. Rev. Pharmacol. Toxicol. 47 (2007) 263-292
10. Wirth H., and Wermuth B. Immunohistochemical localization of carbonyl reductase in human tissues. J. Histochem. Cytochem. 40 (1992) 1857-1863
11. Penning T.M., Burczynski M.E., Jez J.M., Lin H.K., Ma H., Moore M., Ratnam K., and Palackal N. Structure-function aspects and inhibitor design of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3). Mol. Cell. Endocrinol. 171 (2001) 137-149
12. Lopez de Cerain A., Marin A., Idoate M.A., Tunon M.T., and Bello J. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoral versus normal tissues. Eur. J. Cancer 35 (1999) 320-324
13. Weiss R.B. The anthracyclines: will we ever find a better doxorubicin?. Semin. Oncol. 19 (1992) 670-686
14. Ramachandran C., Yuan Z.K., Huang X.L., and Krishan A. Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase pi gene expression. Biochem. Pharmacol. 45 (1993) 743-751
15. Soldan M., Netter K.J., and Maser E. Enzymatic detoxification of daunorubicin as supplementary mechanism to multidrug resistance. Exp. Toxic. Pathol. 48 Suppl. II (1996) 370-376
16. J. Michalsky, International Patent Application, PCT/CS92/00026 (1992).
17. Wsol V., Kvasnickova E., Szotakova B., and Hais I.M. High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracin. J. Chromatogr. B Biomed. Appl. 681 (1996) 169-175
18. Szotakova B., Wsol V., Trejtnar F., Skalova L., and Kvasnickova E. Studies on the metabolism of the potential cytostatic drug oracin. Species differences. Exp. Toxicol. Pathol. 48 Suppl. II (1996) 377-380
19. Wsol V., Szotakova B., Skalova L., Cepkova H., and Kvasnickova E. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin. Enantiomer 5 (2000) 263-270
20. Wsol V., Szotakova B., Skalova L., and Maser E. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1. Toxicology 197 (2004) 253-261
21. Wsol V., Szotakova B., Skalova L., and Maser E. Contribution of aldo-keto reductases to the metabolism of the novel anticancer drug oracin in man. Enzymol. Mol. Biol. Carbonyl Metab. 12 (2005) 249-255
22. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., and Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150 (1985) 76-85
23. Fogli S., Danesi R., Innocenti F., Di Paolo A., Bocci G., Barbara C., and Del Tacca M. An improved HPLC method for therapeutic drug monitoring of daunorubicin, idarubicin, doxorubicin, epirubicin and their 13-dihydro metabolites in human plasma. Ther. Drug Monit. 21 (1999) 367-375
24. Wsol V., Szotakova B., Skalova L., and Maser E. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1. Chem. Biol. Interact. 143-144 (2003) 459-468
25. -ΔΔCT method. Methods 25 (2001) 402-408
26. Peterson G.L. Rewiev of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Anal. Biochem. 100 (1979) 201-220
27. Duan L., Sterba K., Kolomeichuk S., Kim H., Brown P.H., and Chambers T.C. Inducible overexpression of c-Jun in MCF7 cells causes resistance to vinblastine via inhibition of drug-induced apoptosis and senescence at a step subsequent to mitotic arrest. Biochem. Pharmacol. 73 (2007) 481-490
28. Mansilla S., Rojas M., Bataller M., Priebe W., and Portugal J. Circumvention of the multidrug-resistance protein (MRP1) by an antitumor drug through specific inhibition of gene transcription in breast tumor cells. Biochem. Pharmacol. 73 (2007) 934-942
29. Bauman D.R., Steckelbroeck S., and Penning T.M. The roles of aldo-keto reductases in steroid hormone action. Drug News Perspect. 17 (2004) 563-578
30. Vihko P., and Isomaa V. 17beta-hydroxysteroid dehydrogenases and breast cancer. Cancer Ther. 3 (2005) 543-550
31. Bauman D.R., Rudnick S.I., Szewczuk L.M., Jin Y., Gopishetty S., and Penning T.M. Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes. Mol. Pharmacol. 67 (2005) 60-68
32. Usami N., Yamamoto T., Shintani S., Ishikura S., Higaki Y., Katagiri Y., and Hara A. Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol. Pharm. Bull. 25 (2002) 441-445
33. Brozic P., Golob B., Gomboc N., Rizner T.L., and Gobec S. Cinnamic acids as new inhibitors of 17beta-hydroxysteroid dehydrogenase type 5 (AKR1C3). Mol. Cell. Endocrinol. 248 (2006) 233-235
34. Slupe A., Williams B., Larson C., Lee L.M., Primbs T., Bruesch A.J., Bjorklund C., Warner D.L., Peloquin J., Shadle S.E., Gambliel H.A., Cusack B.J., Olson R.D., and Charlier Jr. H.A. Reduction of 13-deoxydoxorubicin and daunorubicinol anthraquinones by human carbonyl reductase. Cardiovasc. Toxicol. 5 (2005) 365-376
35. Martin H.J., Breyer-Pfaff U., Wsol V., Venz S., Block S., and Maser E. Purification and characterization of AKR1B10 from human liver: role in carbonyl reduction of xenobiotics. Drug Metab. Dispos. 34 (2006) 464-470
36. Gajewski E., Gaur S., Akman S.A., Matsumoto L., van Balgooy J.N.A., and Doroshhow J.H. Oxidative DNA damage in MCF-10A breast epithelial cells at clinically achievable concentrations of doxorubicin. Biochem. Pharmacol. 73 (2007) 1947-1956
37. Ax W., Soldan M., Koch L., and Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 59 (2000) 293-300
38. Akman S.A., Forrest G., Chu F.-F., Esworthy R.S., and Doroshow J.H. Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res. 50 (1990) 1397-1402